AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

Great News for AbbVie Stock Investors - Yahoo Finance

Acquisition Dividend Drug approval AI-generated analysis

πŸ“ˆ AbbVie shares have risen 26% this year supported by strong financial results and a robust pipeline.

πŸ’Š Skyrizi generated nearly $10 billion in sales for the first half of the year, up 27% year over year.

πŸ”¬ Phase 2a results for next-gen drug ABBV-466 showed higher remission rates in Crohn's disease than current treatments.

πŸ’° AbbVie acquired Apogee Therapeutics for $10.9 billion to bolster its immunology portfolio with zumilokibart.

πŸ“… Rinvoq is protected from generic competition in the U.S. market until 2037.

πŸ† The company holds Dividend King status with 50 consecutive years of dividend increases and a 2.5% forward yield.

Bullish Signals
  • AbbVie shares have climbed 26% year-to-date driven by strong financial performance and a bright medium-term outlook.
  • Skyrizi generated nearly $10 billion in sales for the first half of the year, representing a 27% increase over the prior period.
  • Phase 2a results for next-gen drug ABBV-466 showed higher remission rates in Crohn's disease than current monotherapies, suggesting a strong successor to Skyrizi.
  • The company acquired Apogee Therapeutics for $10.9 billion to gain access to zumilokibart, a potential blockbuster competitor to Sanofi's Dupixent.
  • Rinvoq is protected from generic competition in the U.S. market until 2037, ensuring sustained revenue growth.
  • AbbVie holds Dividend King status with 50 consecutive years of dividend increases and offers a forward yield of 2.5%.
Full Analysis
AbbVie (NYSE: ABBV) shares have climbed 26% year-to-date driven by strong financial performance and a bright medium-term outlook. The company's two primary growth pillars, Skyrizi and Rinvoq, are performing robustly, with Skyrizi generating nearly $10 billion in sales for the first half of the year, representing a 27% increase over the prior period. To mitigate future patent expirations, AbbVie is advancing next-generation therapies. On October 19, the company announced positive Phase 2a results for ABBV-466, a combination immunology drug showing higher remission rates in Crohn's disease than current monotherapies. Additionally, the firm recently acquired Apogee Therapeutics for $10.9 billion to gain access to zumilokibart, a potential competitor to Sanofi's Dupixent. Beyond its core immunology portfolio, AbbVie maintains strong positions in other therapeutic areas including migraine (Qulipta), schizophrenia (Vraylar), and oncology (Venclexta). The company also boasts an attractive dividend profile as a Dividend King with 50 consecutive years of increases and a forward yield of 2.5%, significantly outpacing the S&P 500 average.